Adeno-Associated Virus Vectors in Gene Therapy
Adeno-Associated Virus Vectors in Gene Therapy Market

Gene therapy is a promising treatment option for several diseases and involves vectors, either viral or non-viral vectors. 


Out of the several viral vectors that have been used for delivering the genes of interest, the Adeno-associated viral (AAV) vector appears to be the safest and effective vehicle and can maintain long-term gene and protein expression following a single injection of the vector. 


Adeno-Associated Virus Vectors in Gene Therapy Epidemiological Segmentation 

The Epidemiological Segmentation of Adeno-Associated Virus Vectors in Gene Therapy in 7MM from 2017 to 2030 is segmented as:- 

  • Total prevalent cases of selected indications
  • Total indication wise eligible cases
  • Indication wise Treated Cases of AAV Gene Therapies 


Adeno-Associated Virus Vectors in Gene Therapy Epidemiology 

  • The total prevalent cases of selected indications for AAV Gene Therapies in 7MM were 2,718,559 in 2017. 
  • The highest number of prevalent cases was in Germany, with 428,198 cases in 2017. 


Adeno-Associated Virus Vectors in Gene Therapy Market

The total market size of AAV-vector-based Gene Therapy in 7MM in 2019 was USD 428 million.


Adeno-Associated Virus Vectors in Gene Therapy Market Drivers

  • Ability to treat a broad array of conditions
  • AAV Capsid Selection and Optimization
  • Longer Transgene Expression


Adeno-Associated Virus Vectors in Gene Therapy Market Barriers

  • Shortcomings of AAV based Gene Therapies
  • Failures and risks associated with clinical trials 


Adeno-Associated Virus Vectors in Gene Therapy Emerging Drugs

The emerging drugs of the Adeno-Associated Virus Vectors in the Gene Therapy market are 

  • Valoctocogene Roxaparvovec (BMN 270)
  • RG6357 (SPK-8011)
  • Fidanacogene elaparvovec (SPK-9001/ PF-06838435)
  • AT-GTX-502/scAAV9.P546.CLN3
  • Timrepigene emparvovec/BIIB111/AAV2-REP1
  • SGT-001
  • FLT190
  • RGX-121

And many others. 


Adeno-Associated Virus Vectors in Gene Therapy Key Players

The key players in the Adeno-Associated Virus Vectors in Gene Therapy market are

  • BioMarin Pharmaceutical
  • Roche 
  • Spark Therapeutics
  • Pfizer 
  • Amicus Therapeutics
  • NightstaRx Ltd
  • Solid Biosciences
  • Freeline Therapeutics
  • Regenxbio

And many others.